According to WHO's latest report, Belarus is listed as a multidrug-resistant TB high burden country. We are supporting the Ministry of Health in four TB facilities across Minsk city and region. Minsk is also a site for two clinical studies into shorter, innovative TB regimens which use newer TB drugs, TB PRACTECAL and endTB.
In Orsha, teams also treat inmates of a prison with DR-TB and co-infections such as hepatitis C, for which they receive direct-acting antiviral drugs.
Our activities in 2022 in Belarus
Data and information from the International Activity Report 2022.
29
29
€1.3 M
1.3M
2015
2015


340
34

Voices from the field
This experience has changed our outlook on life.Polina, a patient taking part in MSF's TB trial

A revolution in TB treatment leads to safer and more effective practice

MSF leaves Polish border after being blocked from assisting people

8 things to know about the EU/Belarus border crisis

TB patients improve treatment adherence with psychological and social support
